Discontinued — last reported Q1 '26
Business Segments · Restructuring Reserve, Settled without Cash
U.S. Pharmaceutical — Restructuring Reserve, Settled without Cash
McKesson U.S. Pharmaceutical — Restructuring Reserve, Settled without Cash decreased by 100.0% to $0.00 in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $1.00M to $0.00. Over 2 years (FY 2022 to FY 2024), U.S. Pharmaceutical — Restructuring Reserve, Settled without Cash shows a downward trend with a -52.9% CAGR.
Analysis
StatementSegment
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ1 2020
Last reportedQ1 2026Aug 6, 2025
Rolls up toRestructuring Reserve Settled Without Cash2
How to read this metric
High non-cash settlement suggests the company is utilizing existing assets to satisfy obligations, preserving cash flow.
Detailed definition
This metric tracks the portion of restructuring reserves in the U.S. Pharmaceutical segment that were settled through no...
Peer comparison
Specific to accounting disclosures regarding the settlement of restructuring accruals.
Metric ID:
mck_segment_u_s_pharmaceutical_restructuring_reserve_settled_without_cashHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.00M | $8.00M | $0.00 | $2.00M | $0.00 | $3.00M | $1.00M | $21.00M | $0.00 | $0.00 | $0.00 | $4.00M | $1.00M | $63.00M | $1.00M | $0.00 |
| QoQ Change | — | +0.0% | -100.0% | — | -100.0% | — | -66.7% | >999% | -100.0% | — | — | — | -75.0% | >999% | -98.4% | -100.0% |
| YoY Change | — | — | — | — | -100.0% | -62.5% | — | +950.0% | — | -100.0% | -100.0% | -81.0% | — | — | — | -100.0% |
Range$0.00 – $63.00M
CAGR-100.0%
Avg YoY Growth+58.1%
Median YoY Growth-100.0%
Current Streak2 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — restructuring reserve, settled without cash?
- McKesson (MCK) reported u.s. pharmaceutical — restructuring reserve, settled without cash of $0.00 in Q2 2025.
- How has McKesson's u.s. pharmaceutical — restructuring reserve, settled without cash changed year-over-year?
- McKesson's u.s. pharmaceutical — restructuring reserve, settled without cash decreased by 100.0% year-over-year, from $1.00M to $0.00.
- What is the long-term trend for McKesson's u.s. pharmaceutical — restructuring reserve, settled without cash?
- Over 2 years (2022 to 2024), McKesson's u.s. pharmaceutical — restructuring reserve, settled without cash has grown at a -52.9% compound annual growth rate (CAGR), from $18.00M to $4.00M.
- What does u.s. pharmaceutical — restructuring reserve, settled without cash mean?
- Restructuring costs paid using non-cash assets rather than cash.